Stock Analysis

China Medical System Holdings Full Year 2023 Earnings: Misses Expectations

Source: Shutterstock

China Medical System Holdings (HKG:867) Full Year 2023 Results

Key Financial Results

  • Revenue: CN¥8.01b (down 12% from FY 2022).
  • Net income: CN¥2.40b (down 26% from FY 2022).
  • Profit margin: 30% (down from 36% in FY 2022). The decrease in margin was driven by lower revenue.
  • EPS: CN¥0.98 (down from CN¥1.33 in FY 2022).

867 Products In Clinical Trials

  • Phase I: 1.
  • Phase II: 5.
  • Phase III: 5.

867 Post-Clinical Trial Products

  • Pre-registration: 2.
  • Approved (during full year): 3.
SEHK:867 Earnings and Revenue Growth April 20th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Medical System Holdings Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 27%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are down 3.0% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with China Medical System Holdings, and understanding these should be part of your investment process.

Valuation is complex, but we're helping make it simple.

Find out whether China Medical System Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.